Kocurin, the True Structure of PM181104, an Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Thiazolyl Peptide from the Marine-Derived Bacterium  Kocuria palustris

Martín, Jesús; Sousa, Thiciana da Silva; Crespo, Gloria; Palomo, Sara; González, Ignacio; Tormo, José R.; Cruz, Mercedes de la; Anderson, Matthew A.; Hill, Russell T.; Vicente, Francisca; Genilloud, Olga; Reyes, Fernando

doi:10.3390/md11020387

Cited by 76 publications

(59 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compounds 1 – 4 were tested for their ability to inhibit the growth of Gram negative and Gram positive bacteria ( E. coli MB2884 and methicillin-resistant S. aureus MRSA, MB5393), fungi ( A. fumigatus ATCC46645), and yeast ( C. albicans MY1055) following previously described methodologies [26,27,28]. Briefly, each compound was serially diluted in DMSO with a dilution factor of two to provide ten concentrations starting at 64 μg/mL for all the assays.…”

Section: Methodsmentioning

confidence: 99%

MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078

et al. 2016

Self Cite

View full text Add to dashboard Cite

A new napyradiomycin, MDN-0170 (1), was isolated from the culture broth of the marine-derived actinomycete strain CA-271078, together with three known related compounds identified as 4-dehydro-4a-dechloronapyradiomycin A1 (2), napyradiomycin A1 (3) and 3-chloro-6,8-dihydroxy-8-α-lapachone (4). The structure of the new compound was determined using a combination of spectroscopic techniques, including 1D and 2D NMR and electrospray-time of flight mass spectrometry (ESI-TOF MS). The relative configuration of compound 1, which contains two independent stereoclusters, has been established by molecular modelling in combination with nOe and coupling constant analyses. Biosynthetic arguments also allowed us to propose its absolute stereochemistry. The antimicrobial properties of the compounds isolated were evaluated against methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Aspergillus fumigatus, and Candida albicans. The potent bioactivity previously reported for compounds 2 and 3 against methicillin-sensitive S. aureus has been extended to methicillin-resistant strains in this report.

show abstract

Section: Methodsmentioning

confidence: 99%

MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are quite a few molecules reported from the class of PM181104 (10,15). Most of them presented good in vitro activity against Gram-positive strains, especially MRSA.…”

Section: Discussionmentioning

confidence: 99%

“…strain MI-67-EC3-038 (11). Interestingly, the former report (10) claims that kocurin and compound PM181104 are identical molecules, and the structure of kocurin (Fig. 1) is indeed the more acceptable structure of PM181104.…”

mentioning

confidence: 99%

See 1 more Smart Citation

In Vitro and In Vivo Activities of Antibiotic PM181104

Mahajan

Thomas

Parab

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

bDrug resistance has become a global threat that, if not addressed, may return us to the preantibiotic era. A way to overcome the problem of growing incidence of global antibiotic resistance is to introduce compounds belonging to classes that are new to the clinic. During a screening of the marine microbial extract library for new antibiotics, one of the extracts showed promising antibacterial activity against Gram-positive organisms. Bioactivity-guided isolation and characterization of active metabolites led to the discovery of a novel thiazolyl cyclic-peptide antibiotic, PM181104. It was isolated and characterized from a marine spongeassociated actinobacterium strain of the genus Kocuria (MTCC 5269). The compound exhibited a potent in vitro antibacterial activity against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The MIC values evaluated for the compound were found to be in the single-digit nanomolar range. In in vivo studies of PM181104 in a BALB/c murine septicemia model, the compound displayed 100% effective dose (ED 100 ) values of 2.5 and 5.0 mg/kg of body weight against MRSA and 10.0 mg/kg against VRE. In this report, in vitro and in vivo studies of PM181104 are described.

show abstract

“…[49]; a novel bisindole alkaloid hyrtimomine D ( 36 ), isolated from an Okinawan marine sponge Hyrtios sp. [50]; a new bromotyrosine-derived metabolite, ianthellisformisamine A ( 37 ), reported from the Australian marine sponge Suberea ianthelliformis [51]; a new thiazolyl peptide kocurin ( 38 ) from the marine-derived bacterium Kocuria palustris [52]; the known alkaloid lamellarin O ( 39 ), isolated from a southern Australian sponge Ianthella sp. [53]; three new halogenated sesquiterpenes ( 40 – 42 ), isolated from the Chinese marine red alga Laurencia okamurai [54]; a new spirotetronate antibiotic, lobophorin H ( 43 ) from a South China Sea- Streptomyces sp.…”

Section: Marine Compounds With Antibacterial Antifungal Antiprotmentioning

confidence: 99%

Marine Pharmacology in 2012–2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

et al. 2017

View full text Add to dashboard Cite

The peer-reviewed marine pharmacology literature from 2012 to 2013 was systematically reviewed, consistent with the 1998–2011 reviews of this series. Marine pharmacology research from 2012 to 2013, conducted by scientists from 42 countries in addition to the United States, reported findings on the preclinical pharmacology of 257 marine compounds. The preclinical pharmacology of compounds isolated from marine organisms revealed antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral and anthelmitic pharmacological activities for 113 marine natural products. In addition, 75 marine compounds were reported to have antidiabetic and anti-inflammatory activities and affect the immune and nervous system. Finally, 69 marine compounds were shown to display miscellaneous mechanisms of action which could contribute to novel pharmacological classes. Thus, in 2012–2013, the preclinical marine natural product pharmacology pipeline provided novel pharmacology and lead compounds to the clinical marine pharmaceutical pipeline, and contributed significantly to potentially novel therapeutic approaches to several global disease categories.

show abstract

Kocurin, the True Structure of PM181104, an Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Thiazolyl Peptide from the Marine-Derived Bacterium Kocuria palustris

Cited by 76 publications

References 10 publications

MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078

MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078

In Vitro and In Vivo Activities of Antibiotic PM181104

Marine Pharmacology in 2012–2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Contact Info

Product

Resources

About